A Phase III, Open-Label, Randomized Study of On-Demand TACE Combined With Atezolizumab Plus Bevacizumab (Atezo/Bev) or On-Demand TACE Alone in Patients With Untreated Heaptocellular Carcionma
Latest Information Update: 23 Feb 2024
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary)
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Acronyms TALENTACE
- Sponsors Roche
- 31 Aug 2023 Status changed from recruiting to active, no longer recruiting.
- 20 Apr 2023 The time frame of primary endpoint changed.
- 13 Dec 2022 Planned End Date changed from 1 Sep 2028 to 28 Feb 2029.